Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab and Rituximab

BACKGROUND: CLL patients are usually only treated for progressive disease. However, the discovery of biological predictors of high risk of disease progression together with the development of newer more targeted therapies could change this paradigm. In this phase 2 study we tested the safety and eff...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zent, Clive S., Call, Timothy G., Shanafelt, Tait D., Tschumper, Renee T., Jelinek, Diane F., Bowen, Deborah A., Secreto, Charla R., LaPlant, Betsy R., Kabat, Brian F., Kay, Neil E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2849723/
https://ncbi.nlm.nih.gov/pubmed/18759253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23824
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados